Premium
The GUSTO 2b and related studies
Author(s) -
Aylward Philip
Publication year - 1998
Publication title -
australian and new zealand journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 0004-8291
DOI - 10.1111/j.1445-5994.1998.tb02108.x
Subject(s) - hirudin , medicine , timi , discovery and development of direct thrombin inhibitors , st elevation , thrombin , heparin , cardiology , thrombolysis , myocardial infarction , platelet
Direct anti‐thrombin inhibitors such as hirudin have theoretical advantages over heparin. Two large studies in acute coronary syndromes were designed to test the thrombin hypothesis by demonstrating improved outcomes in hirudin treated patients. TIMI 9 assessed the effect of hirudin in patients with ST elevation receiving thrombolytic therapy. GUSTO 2 assessed the full spectrum of acute coronary syndromes of ST elevation and non‐ST elevation. Over 15,000 patients were entered into the studies and no major benefit was demonstrated for hirudin. This may, however, relate to endpoints measured and the timing of the anti‐thrombin.